Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Episode 389

0:00-37:22

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and lingering questions about her independence, new pharma tariff guidance that leaves exemptions unclear, and how reverse mergers paired with nine-figure PIPEs became a viable IPO alternative. Plus, Merck's $400 million upfront bet on a preclinical KRAS G12C molecular glue. View full story: https://www.biocentury.com/article/660935 #IgANephropathy #FDA #BiotechIPO #DrugDevelopment #ClinicalTrials 0:00 Introduction 1:30 Grand Rounds: Europe Recap 6:03 IgA Nephropathy Pipeline 14:57 Overton Hearing 22:19 Commerce's Tariff Guidance 24:28 Reverse Mergers' New Look To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Publisher

BioCentury This Week

Published

September 29, 2026

Duration

37 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BioCentury

BT

BioCentury This Week

@biocenturythisweek

#iganephropathy #overtonhearing #reversemergers #lifesciences

The Nile